Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Trial 2 to Assess MK-8342B Treatment Efficacy-Safety in Dysmenorrhea
In women with moderate to severe primary dysmenorrhea: 1. To evaluate the efficacy of the ENG-E2 vaginal ring relative to placebo in the treatment of dysmenorrhea at Treatment Cycle 2. 2. To a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A trial investigating how well pembrolizumab works in treating patients with relapsed or refractory Primary Mediastinal Large B-Cell Lymphoma Un ensayo de investigación de como funciona el pembrolizumab en el tratamiento de pacientes con linfoma mediastínico primario de linfocitos B grandes recidivante o resistente
To evaluate the Overall Response Rate (ORR) of pembrolizumab by independent central review according to the International Working Group (IWG) response criteria (Cheson, 2007) Evaluar la tasa de ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
MK-0518B EU Bioequivalence Study
To evaluate the comparative bioavailability between: •Raltegravir/lamivudine (MK-0518B) 300 mg/150 mg Fixed-Dose Combination (FDC) tablets from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Study to correlate a new biomarker (ST2) with clinical activity in Ulcerative Colitis patients under golimumab
- To evaluate the correlation of serum soluble ST2 levels with endoscopic activity (endoscopic Mayo score) at week 6 in moderate to severe UC subjects under golimumab treatment. - To evaluate the co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pembrolizumab as First Line Treatment in Subjects with Recurrent/Metastatic HNSCC
1) To compare the Progression Free Survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR) in a subgroup of first line recurrent/metastatic (R/M) head and neck squamous ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
EBR/GBR + SOF +/- RBV in Cirrhotic GT3 Subjects
(1) Objective: To evaluate the efficacy of each treatment arm of GZR/EBR (MK-5172A) in combination with Sofosbuvir (SOF) +/- Ribavirin (RBV) as assessed by the proportion of subjects achieving SVR12 (...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Ph 3 Placebo-Controlled Trial of Adjuvant MK-3475 in RCC Post Nephrectomy
To compare disease-free survival (DFS) as assessed by the investigator for participants treated with pembrolizumab versus those receiving placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Effect of reversing muscle relaxation with sugammadex compared with usual care on bleeding risk in patients on blood thinners undergoing major joint surgery
To assess the effect of reversal of neuromuscular blockade with sugammadex 4 mg.kg-1 compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of adjudicate...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast Cancer
Part 1 (Safety Run-In): Objective: To evaluate the safety and tolerability of 3 pembrolizumab + chemotherapy combinations, namely, pembrolizumab + paclitaxel, pembrolizumab + nab paclitaxel, and pem...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphoma
(1) Objective: To define the rate of dose-limiting toxicities (DLTs) at the maximum tolerated dose (MTD) or maximum administered dose (MAD) of pembrolizumab when administered as monotherapy to child...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16
Suivant